Back to search

Article

The Potential Antitumor Effects of Combining Intravesical Therapy with Recombinant Bacillus Calmette-Guérin and an Immune Checkpoint Inhibitor in Bladder Cancer

2025-07-15

Abstract excerpt

<title>Abstract</title> <p> Background Recombinant Bacillus Calmette-Guérin (rBCG) is a genetically modified BCG that enhances therapeutic efficacy and safety in patients with bladder cancer. Pembrolizumab is an immune checkpoint inhibitor that is used to treat bladder cancer. We aimed to evaluate the effectiveness of the combination of rBCG and pembrolizumab in <italic>in vitro</italic> and <italic>in vivo</...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b7b70230-0dfc-5f0f-b789-3cc01e35b94b
DOI
10.21203/rs.3.rs-6798208/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Potential Antitumor Effects of Combining Intravesical Therapy with Recombinant Bacillus Calmette-Guérin and an Immune Checkpoint Inhibitor in Bladder CancerDOI 10.21203/rs.3.rs-6798208/v1
Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studiesSemantic proximity
Comparison of intravesical instillation of Bacille Calmette-Guérin and epirubicin: a randomized controlled trialSemantic proximity
Targeting CXCR4-expressing TAMs in muscle-invasive bladder cancer to enhance tumor control after immunotherapySemantic proximity
A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder CancerSemantic proximity
Modeling adaptive therapy in non-muscle invasive bladder cancerSemantic proximity
Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder CancerSemantic proximity
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.Semantic proximity
Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancerSemantic proximity
Microbial cancer immunotherapy reprograms hematopoiesis to enhance anti-tumor immunitySemantic proximity
Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid StructuresSemantic proximity
A Novel CpG Oligodeoxynucleotide Enhanced the Therapeutic Effect of Epirubicin on Bladder Tumors in RatsSemantic proximity
Select a neighboring publication to make it the new centre.